Editorial
Combination of Immunotherapy and Radiotherapy—The Next Magic Step in the Management of Lung Cancer?

https://doi.org/10.1016/j.jtho.2019.12.106Get rights and content
Under an Elsevier user license
open archive

Keywords

NSCLC
SCLC
Immune checkpoint inhibitors
Radiotherapy

Cited by (0)

Disclosure: Dr. Hendriks: none related to the current manuscript; outside of the current manuscript—research funding: Roche, Boehringer Ingelheim, and AstraZeneca (all institutions); advisory board: Boehringer, BMS, Lilly, Roche, and Pfizer (all institutions); speaker: MSD; travel/conference reimbursement: Roche, BMS (self); mentorship program with key opinion leaders: funded by AstraZeneca; fees for educational webinars: Quadia (self). Dr. Menis: none related to the current manuscript; outside of the current manuscript—advisory: BMS, Boehringer Ingelheim, MSD, and Roche; travel: Boehringer Ingelheim, Ipsen, MSD, BMS, and AstraZeneca. Dr De Ruysscher—research funding: Boehringer Ingelheim, Bristol-Myers Squibb, AstraZeneca, Philips, and Olink (all institutions); advisory board: Bristol-Myers Squibb, Celgene, Merck/Pfizer, Roche/Genentech, AstraZeneca, MSD, and Seattle Genetics (all institutions). Dr. Reck: none related to the current manuscript; outside of the current manuscript: honoraria for lectures and consultancy from Roche, AbbVie, AstraZeneca, BMS, Boehringer Ingelheim, Celgene, Lilly, MSD, Merck, Novartis, Pfizer, and Amgen.